The practical nurse (PN) is reinforcing information with a client who has been diagnosed with human immunodeficiency virus (HIV) about the antiretroviral medication regimen. Which client statement should the PN recognize as requiring an additional review of the information?

Choice A reason: Polyethylene glycol, a bowel prep for colonoscopy, requires rapid drinking at specified intervals to ensure effective colon cleansing. This osmotic laxative draws water into the bowel, promoting evacuation. Consistent, rapid intake ensures complete bowel clearance, critical for clear visualization during the procedure.

Choice B reason: Diluting polyethylene glycol with fruit juice is incorrect, as it may alter the solution’s osmotic balance, reducing efficacy. The preparation must remain undiluted to draw sufficient water into the colon for cleansing, making this instruction inappropriate for achieving a clear colonoscopy.

Choice C reason: Drinking polyethylene glycol with a meal is incorrect, as food can interfere with bowel cleansing. The solution is taken on an empty stomach, typically the day before the exam, to ensure the colon is clear, making this instruction counterproductive to the prep’s purpose.

Choice D reason: Watery diarrhea is the expected outcome of polyethylene glycol, not an adverse effect requiring reporting. It indicates effective bowel cleansing for colonoscopy. Instructing to report this normal response is unnecessary and may cause confusion, as diarrhea is the goal of the preparation.

Choice A reason: Less frequent urinary incontinence is a desired effect of oxybutynin, an antimuscarinic that relaxes bladder muscles, reducing involuntary contractions. This indicates therapeutic success in managing overactive bladder, not a concern requiring reporting, as it aligns with the drug’s intended action.

Choice B reason: Diminished urinary urgency is an expected outcome of oxybutynin, which inhibits bladder spasms by blocking acetylcholine receptors. This reduces the urge to urinate, improving overactive bladder symptoms, and does not warrant reporting, as it reflects the medication’s efficacy.

Choice C reason: Decreased urinary output is concerning, as oxybutynin’s anticholinergic effects may cause urinary retention by overly relaxing the bladder. This risks bladder distension or infection, requiring reporting to assess for obstruction or adjust dosing, making this the critical finding to address.

Choice D reason: Reduced urinary frequency is a therapeutic effect of oxybutynin, which decreases bladder contractions, allowing longer intervals between urination. This is a goal of overactive bladder treatment and does not require reporting, as it indicates the drug is working as intended.